ADMA Biologics (NASDAQ:ADMA) Price Target Raised to $32.00

ADMA Biologics (NASDAQ:ADMA) had its price target raised by Raymond James from $25.00 to $32.00 in a report issued on Thursday,Benzinga reports. They currently have a strong-buy rating on the biotechnology company’s stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $19.99 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a 50 day moving average price of $20.23 and a 200-day moving average price of $18.74. ADMA Biologics has a 1-year low of $8.42 and a 1-year high of $25.67. The firm has a market cap of $4.75 billion, a price-to-earnings ratio of 71.39 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. During the same period in the previous year, the company earned $0.08 earnings per share. The company’s revenue was up 40.2% compared to the same quarter last year. Equities research analysts forecast that ADMA Biologics will post 0.51 EPS for the current year.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in ADMA Biologics during the 4th quarter worth $35,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics during the first quarter worth $35,000. Vision Financial Markets LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at about $51,000. Finally, Tsfg LLC purchased a new position in shares of ADMA Biologics in the first quarter worth about $51,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.